Atomoxetine Prevents Dexamethasone-Induced Skeletal Muscle Atrophy in Mice
- 1 December 2014
- journal article
- research article
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 351 (3) , 663-673
Abstract
Skeletal muscle atrophy remains a clinical problem in numerous pathologic conditions. β2-Adrenergic receptor agonists, such as formoterol, can induce mitochondrial biogenesis (MB) to prevent such atrophy. Additionally, atomoxetine, an FDA-approved norepinephrine reuptake inhibitor, was positive in a cellular assay for MB. We used a mouse model of dexamethasone-induced skeletal muscle atrophy to investigate the potential role of atomoxetine and formoterol to prevent muscle mass loss. Mice were administered dexamethasone once daily in the presence or absence of formoterol (0.3 mg/kg), atomoxetine (0.1 mg/kg), or sterile saline. Animals were euthanized at 8, 16, and 24 hours or 8 days later. Gastrocnemius muscle weights, changes in mRNA and protein expression of peroxisome proliferator–activated receptor-γ coactivator-1 α (PGC-1α) isoforms, ATP synthase β, cytochrome c oxidase subunit I, NADH dehydrogenase (ubiquinone) 1 β subcomplex, 8, ND1, insulin-like growth factor 1 (IGF-1), myostatin, muscle Ring-finger protein-1 (muscle atrophy), phosphorylated forkhead box protein O 3a (p-FoxO3a), Akt, mammalian target of rapamycin (mTOR), and ribosomal protein S6 (rp-S6; muscle hypertrophy) in naive and muscle-atrophied mice were measured. Atomoxetine increased p-mTOR 24 hours after treatment in naïve mice, but did not change any other biomarkers. Formoterol robustly activated the PGC-1α-4-IGF1–Akt-mTOR-rp-S6 pathway and increased p-FoxO3a as early as 8 hours and repressed myostatin at 16 hours. In contrast to what was observed with acute treatment, chronic treatment (7 days) with atomoxetine increased p-Akt and p-FoxO3a, and sustained PGC-1α expression and skeletal muscle mass in dexamethasone-treated mice, in a manner comparable to formoterol. In conclusion, chronic treatment with a low dose of atomoxetine prevented dexamethasone-induced skeletal muscle wasting and supports a potential role in preventing muscle atrophy.Keywords
This publication has 43 references indexed in Scilit:
- β2-Adrenoceptor agonists in the regulation of mitochondrial biogenesisBioorganic & Medicinal Chemistry Letters, 2013
- Glucocorticoid-induced skeletal muscle atrophyThe International Journal of Biochemistry & Cell Biology, 2013
- Cellular and molecular mechanisms of muscle atrophyDisease Models & Mechanisms, 2013
- A PGC-1α Isoform Induced by Resistance Training Regulates Skeletal Muscle HypertrophyCell, 2012
- Muscle Plasticity and β2‐Adrenergic Receptors: Adaptive Responses of β2‐Adrenergic Receptor Expression to Muscle Hypertrophy and AtrophyBioMed Research International, 2011
- Dexamethasone Represses Signaling through the Mammalian Target of Rapamycin in Muscle Cells by Enhancing Expression of REDD1Journal of Biological Chemistry, 2006
- Effects of chronic administration of clenbuterol on function and metabolism of adult rat cardiac muscleAmerican Journal of Physiology-Heart and Circulatory Physiology, 2005
- REGULATION OF MUSCLE MASS BY MYOSTATINAnnual Review of Cell and Developmental Biology, 2004
- Autocrine and/or Paracrine Insulin-Like Growth Factor-I Activity in Skeletal MuscleClinical Orthopaedics and Related Research, 2002
- Facilitatory and Inhibitory Effects of Selective Norepinephrine Reuptake Inhibitors on Hypogastric Nerve-Evoked Urethral Contractions in the Cat: A Prominent Role of Urethralβ-Adrenergic ReceptorsJournal of Urology, 1994